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IT-001: APPROPRIATE EXTENT OF RESECTION FOR THYMOMA 
WITH RESPECT TO RECURRENCE
Mi Kyung Bae, Lee Seokkee, Seong Yong Park, Changyoung Lee, Jin Gu Lee, Dae Joon 
Kim, Kyung Young Chung  
Department Of Thoracic And Cardiovascular Surgery, Yonsei University Health System, 
Yonsei University College Of Medicine, Seoul/KOREA
Background: Complete thymectomy has been widely supported for thymoma resection 
because intrathymic metastasis or multicentric development of thymomas can lead 
to local recurrence in remnant thymic tissues. However, complete thymectomy and 
thymomectomy have not been compared as a randomized controlled prospective study. 
Moreover, recently, as smaller thymomas have become more readily detectable as a result 
of more advanced imaging technologies, the performance of thymomectomy through 
minimally invasive techniques is also increasing.Thus, at this time, it is important to 
compare the outcomes according to the extent of resection whether thymomectomy is 
appropriate or not. Methods: Between 1986 and 2011, the total of 491 patients underwent 
resection for thymic epithelial tumor with curative intent. Of those, we excluded 
patients with an undetermined World Health Organization (WHO) histologic type 
(n=20), patients with type C thymoma (n=76), and patients who only underwent R1 
(n=32) or R2 resection (n=21). The remaining 342 patients were reviewed retrospectively 
according to extent of resection. Results:  Recurrence was observed in 39 (11.4 %) 
patients. The median time to recurrence was 52 months (range, 6 to 234 months). 
Complete thymectomy was performed in 239 patients (69.9%) and thymomectomy 
was performed 103 patients (30.1%). Patients in complete thymectomy group showed 
significantly higher incidence of myasthenia gravis, histologically more aggressive types 
(WHO B2, B3), more advanced Masaoka-Koga stage (stage III, IV) than thymomectomy 
group. In the complete thymectomy group, 29 recurrences (3 local, 2 local + regional, 
2 local+regional+distant, 18 regional, 4distant) occurred, and in the thymomectomy 
group, 10 recurrences (1 local, 2 local + regional, 7 regional) occurred. Freedom from 
recurrence did not show any significant difference between complete thymectomy group 
and thymomectomy group (freedom from recurrence at 5, 10 and 15 years; 95.4%, 82.7% 
and 71.4% versus 98.9%, 93.8%, 71.1%, p=0.472). When we compared the rate of local 
recurrence in only patients with stage I or II thymoma less than 5 cm, freedom from 
local recurrence between two groups did not show any significant difference (p=0.798). 
Conclusions: Thymomectomy does not show higher risk of recurrence after thymoma 
resection than complete thymectomy. Therefore, thymomectomy might be an alternative 
resection for thymoma resection. However, randomized controlled prospective studies 
are needed to confirm the validity and reliability.  
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IT-002: DOES THE MODE OF SURGICAL RESECTION AFFECT THE 
PROGNOSIS/RECURRENCE IN PATIENTS WITH THYMOMA?
Kazuo Nakagawa, Hiroyuki Sakurai, Shunichi Watanabe, Hisao Asamura  
Thoracic Surgery, National Cancer Center Hospital, Tokyo/JAPAN
Background: Among several controversies in the treatment strategies for patients with 
thymoma, the optimal mode of resection needs to be defined. To explore whether or 
not the mode of resection affects the prognosis/recurrence in patients with thymoma, 
we evaluated the treatment outcome of resected thymomas.  Methods: Two hundred 
nineteen patients with thymoma, who were resected at the National Cancer Center 
Hospital, Tokyo, from 1962 through 2011, were studied retrospectively. The histologic 
subtype of thymoma and the stage were determined according to the WHO histological 
classification and the International Thymic Malignancies Interest Group (ITMIG) 
stage classification, respectively. Patients were divided into two groups, group A 
(thymomectomy group, n = 114) and group B (thymothymectomy group, n = 105). 
The differences in clinicopathological demographics and prognosis were compared 
between two groups. The prognosis was also compared by tumor size (a tumor less than 
5 cm and a tumor 5 cm or more) between two groups.  Results: The clinicopahological 
backgrounds of two groups are summarized in TABLE. Six (5%) patients in group 
A and 8 (8%) in group B had myasthenia gravis postoperatively. The 5- and 10-year 
survival rates of group A were 98% and 96%, and those of group B were 92% and 85%, 
respectively. Among the patients with a tumor less than 5cm, the 5- and 10-year survival 
rates of both groups were 100% and 100%. Among the patients with a tumor 5cm or 
more, the 5- and 10-year survival rates of group A were 98% and 95%, and those of group 
B were 90% and 86%, respectively. Seven (5%) patients in group A and 19 (8%) in group 
B experienced a recurrence. The sites of recurrence were as follows: 1 local, 5 pleural 
dissemination, and 1 distant in group A, and 3 local, 13 pleural dissemination and 3 
distant in group B.  
　 Group A (Thymomectomy) 
Group B 
(Thymothymectomy) 　 
Characteristic (n = 114) (n = 105) P-value 
Age (y) 56.8 ± 13.1 54.6 ± 12.9 0.217 
Gender 0.375 
Male 39 (34%) 42 (40%) 
Female 75 (66%) 63 (60%) 
Tumor size 0.014 
<5 cm 41 (36%) 22 (21%) 
≥5.0 cm 73 (64%) 83 (79%) 
Stage 0.001 
I 47 (42%) 26 (25%) 
II 55 (48%) 48 (46%) 
III 6 (5%) 20 (19%) 
IV 6 (5%) 11 (10%) 
Histologic subtype 0.108 
A 13 (12%) 10 (10%) 
AB 55 (48%) 46 (44%) 
B1 19 (17%) 12 (11%) 
B2 21 (18%) 26 (25%) 
B3 6 (5%) 11 (10%) 
Extent of resection 0.109 
R0 107 (94%) 92 (88%) 
R1/R2 4/3 (6%) 5/8 (12%) 　 
 
Conclusion: There is no difference in prognosis/recurrence between two groups. 
Thymothymectomy might not be always necessary in the treatment of patients with 
thymoma.
Keywords: Thymomectomy, Thymothymectomy, thymoma
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IT-003: LONG-TERM CLINICAL OUTCOMES OF 184 CASES OF 
THYMOMA: ANALYSIS FOR PROGNOSTIC FACTORS AND LYMPH 
NODE DISSECTION
Jae Hyun Jeon, In Kyu Park, Yong Won Seong, Hye Seon Kim, Chang Hyun Kang, Young 
T. Kim  
Thoracic And Cardiovascular Surgery, Seul National University Hospital, Seoul/KOREA
Background: This study aimed to evaluate outcomes of resected thymoma in terms 
of overall survival and freedom from recurrence according to the recommendation of 
the International Thymic Malignancy Interest Group and to analyze implications of 
lymph node dissection.  Methods: A retrospective review was made for 184 patients 
with surgically resected thymoma (WHO type A-B3) between 1995 and 2011 in our 
institution. Clinico-pathologic features and long-term outcome were investigated to 
define prognostic factors for overall survival and freedom from recurrence according 
to Masaoka-Koga stage. Outcomes of lymph node dissection during thymectomy were 
also evaluated.  Results: There were 93 females (50.5%) and mean age was 51.9±12.7 
years. Median follow-up time was 72 months (2-214). Myasthenia gravis was combined 
in 49 patients (26.6%). Clinical stage distributions according to Masaoka-Koga stage 
were: stage I (73 patients), stage II (77), stage III (16), stage IV (18). Complete resection 
was possible in 171 patients (92.9%). There were 4 (2.2%) R1 resections and 9 (4.9%) 
exploration-only cases. The overall 5- and 10-year survival rates were 95.6% and 91.2%, 
respectively. In multivariate analysis, completeness of surgery influenced overall 
survival. Recurrence was diagnosed in patients and median time to recurrence was 
24 months. one patients had local recurrence, 13 had regional recurrence and 2 had 
systemic recurrence. Of the 14 patients with loco-regional metastasis, 10 patients 
received re-resections. The 5-year freedom from recurrence rate was 88.6% (I-92.9%, 
II-89.8%, III-63.5%, IV-51.4%). Stage was an independent risk factor for recurrence in 
multivariate analysis. Lymph node dissection was performed in 106 patients and mean 
number of dissected lymph nodes was 9.7±7.6 (total 1029, range: 1 ~ 34). Total number 
of dissected mediastinal lymph nodes was 709 (upper zone:526, AP zone:139, hilar/
interlobar zone:43, subcarinal zone:1). Lymph node metastases were found in 5 patients 
(upper zone-3, peritumoral-1, peritumoral+hilar zone-1). In subgroup analysis, there 
were no cases of unexpected nodal involvement in 89 thymomas without invasion 
beyond perithymic fat tissues. In contrast, lymph node metastases were found in 5 
(29.4%) cases among 17 thymomas which invaded beyond perithymic tissues (p=0.000). 
Of the 5 patients with lymph node metastasis, 3 patients had R0 resection, and 2 of them 
had recurrence. 
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Figure 1. Kaplan-Meier Curves for freedom from recurrence according to Masaoka-
Koga Stage  Conclusion: Surgical resection of thymoma resulted in favorable long-term 
outcomes. Complete resection and Masaoka-Koga stage were important factors for long-
term survival and recurrence, respectively. Lymph node metastases were significantly 
frequent in locally advanced thymomas. Lymph node dissection must be considered in 
locally advanced thymoma for accurate staging. 
Keywords: thymoma, Prognosis, Masaoka-Koga stage, lymph node metastasis
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IT-004: COMPARISON OF OUTCOME IN THYMOMA AND THY-
MIC CARCINOMA PATIENTS: A MULTICENTER ITALIAN STUDY
Erino Angelo Rendina1, Pier Luigi Filosso2, Enrico Ruffini3, Marco Anile4, Mohsen 
Ibrahim1, Alberto Sandri2, Giulia Bora2, Caterina Casadio5, Alberto Terzi6, Federico 
Venuta4  
1Ospedale Sant’Andrea, University “La Sapienza” In Rome, /ITALY, 2Thoracic Surgery, 
University Of Torino, Torino/ITALY, 3Torino University, /ITALY, 4Fondazione Eleonora 
Lorillard Spencer Cenci; Policlinico Umberto I, University “La Sapienza” In Rome, 
Rome/ITALY, 5Thoracic Surgery, “Amedeo Avogadro” University, Novara/ITALY, 6Unit 
Of Thoracic Surgery, ”Santa Croce E Carle” Hospital, Cuneo/ITALY
Background: Thymic carcinomas’(TCs)biological behavior is more aggressive compared 
to that of Thymomas(THYs),thus showing a poorer prognosis.Aim of this paper is to 
compare the outcome of patients(PTs)operated for THYs and TCs.  Methods: this is a 
multicenter retrospective study of PTs operated for THY and TC in 5 Italian Thoracic 
Surgery Institutions between 1995 and 2010.The exclusion criteria were:PTs with Thymic 
Carcinoid,PTs submitted only to a biopsy and PTs in Masaoka Stage IVB.  Results: 
four hundred eighty one PTs(251 males,52.2%;mean age 53,6±14,2 years)were enrolled: 
438(91.1%)had THY and 43 TC.TCs presented with a higher Masaoka Stage(III-IVA)
(RR 5.42;CI95% 2.57-11.44,p<0.01)and faced an increased risk of being subjected to 
an incomplete surgical resection(RR 9.03;CI95% 6.75-11.97,p=0.03).Overall 5and 
10-year survival rates significantly differed between the two cohorts(THY 88% vs. 
TC 67% at 5-year;THY 78% vs. TC 52% at 10-year,p=0.0005).In TCs,induction and 
adjuvant therapies were more often administered(p=0.0003 induction;p<0.01 adjuvant).
Recurrences occurred in 69 cases(14.4%):in 11 TCs and in 58 THYs, thereby TCs 
had a higher risk to develop recurrences(RR 2.03;CI95% 1.07-3.84, p=0.05).Five-year 
free from relapse rate was significantly higher in THYs(89% vs 70%,p=0.01).At the 
multivariate analysis, Masaoka Stage(p<0.01)and the non-administration of adjuvant 
therapy(p=0.04)were interpreted as negative prognostic factors for relapses. Gender 
(female,p=0.04),TC(p=0.01),high Masaoka Stage(p=0.0001)and incomplete resection 
(p<0.01)were statistically negative prognostic factors of the overall survival.  Conclusion: 
Even if rarer than THY,TCs tend to present with a higher Masaoka Stage and an 
augmented risk of an incomplete surgical resection.Despite the lower 5 and 10-year 
survival rates compared to THYs,with a surgical/oncological multimodal approach an 
acceptable overall survival might be accomplished.
Keywords: thymoma, thymic carcinoma, Relapse, survival
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IT-005: SINGLE CENTER RESULTS OF REDO OPERATION FOR 
RECURRENT THYMOMA
Stefano Margaritora1, Stefano Cafarotti1, Alfredo Cesario1, Filippo Lococo1, Amelia 
Evoli2, Pierluigi Granone1  
1Thoracic Surgery, Catholic University Of Rome, Rome/ITALY, 2Catholic Universithy Of 
Rome, Neuroscience - UCSC, Rome/ITALY
Background: Modes of treatment for recurrent thymoma remain controversial. The aim 
of this study is to analyse the early and long-term results of surgical intervention for this 
condition.  Methods: Between 1970 and 2008, 44 out of 320 patients, who underwent 
resection with radical intent for thymoma, subsequently relapsed. Of these, 30 cases were 
deemed suitable for resection and operation, and were surgically treated. The remaining 
14 were treated with radio- and/or chemotherapy (RT/CT). Overall outcomes for long-
term survival up to 5 years (LTS) and disease-free survival (DFS) were analysed using 
standard statistics  Results: The average age of the relapsed patients was 54.7±12.7 years. 
There were 21 males and 23 females. Forty out of the 44 had myasthenia gravis (MG). 
Fifteen cases concerned a single detected relapse lesion. Among the 43 patients, relapses 
were found in the following sites: pleura (26 cases), mediastinum (12), lung (five), liver 
and bone (one). The perioperative mortality was 0% and the morbidity was 27%. Twenty-
two of the surgically treated patients had complete resection; their LTS was 77% and 
DFS was 71%. Those patients who underwent surgery had significantly better outcomes 
compared with patients treated with radio- and/or chemotherapy (LTS only 35%; 
hazard ratio (HR): 0.22; 95% confidence interval (CI): 0.08-0.59; p=0.001). Complete 
repeated resection yielded much better outcomes than partial resection (LTS 91% vs 31%, 
p<0.001), whereas incomplete resection was associated, as one might expect, with a poor 
prognosis (HR: 6.12; 95% CI: 1.18-31.55; p=0.031). No evidence for an association with 
other clinical, surgical and pathological characteristics was found with regard to LTS 
or DFS.  Conclusion: Surgical resection is recommended for the treatment of recurrent 
thymoma, provided that criteria for suitability for resection/operation are satisfactory 
at the time of diagnosis. Best survival outcomes are found to depend on the degree of 
completeness of the repeat resection.
Keyword: recurrent thymoma
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IT-006: RE-RESECTION FOLLOWING RESECTION AND HEATED 
PLEURAL CHEMOPERFUSION FOR THYMOMA WITH PLEURAL 
SPREAD: EVALUATING THE CHALLENGE.
Ronny Ben Avi1, David A. Simansky1, Nona Zeitlin1, Merav Rokah1, Alon Ben Nun1, Alon 
Yellin2  
1Thoracic Surgery, Sheba Medical Center, Ramat Gan/ISRAEL, 2Thoracic Surgery, Sheba 
Medical Center, /ISRAEL
Background: Patients with de-novo stage IVa thymoma and those with pleural relapse 
may be subjected to major operations which occasionally include regional modalities 
such as heated chemical agents, photodynamic therapy, or extensive radiation. The 
aim of the current study is to evaluate the feasibility and difficulties associated with 
redo operations following resection and heated pleural chemoperfusion (HPCP) for 
thymic epithelial tumors (TET).  Methods: A single center retrospective study of 
patients undergoing re-resection following previous HPCP. HPCP was performed with 
Cisplatinum and Adriamycin for 60 minutes with a standard roller pump and a modified 
heat exchanger. Re-resectional operative and postoperative variables were compared 
for each patient with those of the first HPCP using chi square analysis.  Results: Out 
of 35 patients who underwent resection and HPCP for TET, twelve had re-resection 
(9 ipsilateral, 3 contralateral) at an interval of 1-12 yrs. Eight had repeated HPCP and 
4 underwent resection only due mainly to technical difficulties. Severe adhesions 
were noted in 6/9 patients undergoing ipsilateral re-resections. The number of pleural 
implants removed was 1-numerous (median, 8). R0 resection was achieved in 5 patients. 
One patient succumbed to complications 80 days after surgery. There were 2 major and 
3 minor complications. There was no systemic toxicity in patients undergoing re-HPCP. 
Chronic respiratory failure developed in a patient who underwent contralateral HPCP 
following previous pneumonectomy. Compared to the initial operation, re-do operations 
were associated with lengthy adhesiolysis, increased post-operative morbidity and 
mortality (6/11 Vs 1/11), more air leak, longer drainage period, more ICU admission 
and longer hospitalization in spite of the fact that the extent of re-resection was smaller 
than the initial resection.  Conclusion: re-resection after heated pleural chemoperfusion 
maybe a challenging endeavor due to prominent adhesions. A high morbidity/mortality 
rate should be expected. 
Keywords: thymoma, pleural spread, re-resection, heated chemoperfusion
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IT-007: FAILURE PATTERNS AFTER RADIATION THERAPY (RT) 
FOR STAGE II-IV THYMOMA
Andreas Rimner1, Daniel R. Gomez2, Amanda Mclane1, Brad Greenfield2, Andre 
Moreira3, Gregory J. Riely4, Kenneth E. Rosenzweig5, David Rice6, Ritsuko Komaki2, 
Abraham J. Wu1, James Huang7  
1Department Of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New 
York/NY/UNITED STATES OF AMERICA, 2Department Of Radiation Oncology, MD 
Anderson Cancer Center, Houston/TX/UNITED STATES OF AMERICA, 3Department 
Of Pathology, Memorial Sloan-Kettering Cancer Center, New York/NY/UNITED 
STATES OF AMERICA, 4Department Of Medical Oncology, Memorial Sloan-Kettering 
Cancer Center, New York/NY/UNITED STATES OF AMERICA, 5Department Of 
Radiation Oncology, Mount Sinai Medical Center, New York/NY/UNITED STATES OF 
AMERICA, 6Department Of Thoracic Surgery, MD Anderson Cancer Center, Houston/
TX/UNITED STATES OF AMERICA, 7Department Of Thoracic Surgery, Memorial 
Sloan-Kettering Cancer Center, New York/NY/UNITED STATES OF AMERICA
Background: The ideal design of adjuvant or definitive RT fields for thymoma remains 
unclear. We therefore analyzed the failure patterns in patients with stage II-IV thymoma 
treated with RT at two tertiary referral centers in order to identify areas for improvement 
in current RT field design.  Methods: We retrospectively reviewed the failure patterns 
of patients with newly diagnosed stage II-IV thymoma who were treated with definitive 
or adjuvant radiation therapy between 1975 and 2011. Patients with thymic carcinoma 
were excluded. Sites of intrathoracic failures were compared with the radiation plan. 
Intrathoracic failures were categorized according to the ITMIG radiation therapy 
definitions and reporting guidelines as (1) in-field failures (within the 100% isodose 
line (IDL)), (2) marginal recurrences (<100% and ≥50% IDL) and (3) out-of-field failures 
(outside the 50% IDL).  Results: We reviewed 126 patients with a median age of 55 (range 
20 – 88 years), 28% had Masaoka stage II thymoma, 48% had stage III and 24% had 
stage IV disease. Seventy-six patients received chemotherapy. Definitive RT was given 
to 15 patients, and 111 patients had surgery. Of the patients with surgical resection, 
55% had negative margins, while 45% had a positive margin. The median tumor size 
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was 9 cm (range 2 to 20 cm). All patients received involved field RT without elective 
nodal irradiation. The median dose was 5040 cGy in 28 fractions (range 4000-6600cGy). 
With a median followup of 53 months, the 5-year freedom from in-field failure was 
92%. Five-year freedom from any intrathoracic failure was 75% with a median time to 
failure of 29 months. Of the 27 patients with intrathoracic failures, 2 failed within the 
RT field, 1 had a marginal failure, 17 were out-of-field failures, and 7 had synchronous 
recurrences within and outside the RT field. The most common sites of out-of-field 
intrathoracic failure were the pleural space (n=19), followed by the mediastinum (n=7) 
and the lung (n=5). Higher intrathoracic control rates were associated with earlier stage 
(5-year freedom from intrathoracic failure for stage II: 85%; stage III: 81%; stage IV: 45%; 
p=0.008). Margin status, RT dose and use of neoadjuvant or adjuvant chemotherapy did 
not significantly impact the incidence or patterns of in-field or intrathoracic failures. 
Nine patients developed distant metastases, and all occurred in patients who also 
experienced locoregional failure. Five- and 10-year disease-free survival was 75% and 
73%, respectively, and 5- and 10-year overall survival was 88% and 63%, respectively. At 
the end of followup, 7% of patients had died of their disease, 7% were alive with disease, 
and 63% were alive with no evidence of disease.  Conclusion: For patients with thymoma, 
RT is associated with high in-field local control rates. Nevertheless, intrathoracic failures 
still occurred in 1 of 4 patients with the majority outside of the RT field, most commonly 
in the pleural space. Further study is necessary to establish the utility of adjuvant RT and 
decrease the incidence of thymoma recurrences in the pleural space.
Keywords: thymoma, radiation therapy, failure pattern
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IT-008: THE CLINICAL FEATURES OF THYMOMA WITH MYAS-
THENIA GRAVIS
Mitsugu Omasa, Tetsu Yamada, Masaaki Sato, Akihiro Aoyama, Toshihiko Sato, Fengshi 
Chen, Makoto Sonobe, Toru Bando, Hiroshi Date  
Department Of Thoracic Surgery, Kyoto University, 8507/JAPAN
Background: Thymoma is well known to be often associated with myasthenia gravis. 
However, the correlations between thymoma, myasthenia gravis (MG) and titers of anti-
acetylcholine receptor antibody (AchRAb) remain unclear. We analyzed the clinical 
characteristics of thymoma, MG and AchRAb using long-term follow-up data.  Methods: 
We performed operations for 236 patients with thymic epithelial tumor in our institution 
between 1967 and 2012. Of these, 216 cases (105 men, 111 women) with MG information 
were enrolled in the present study. Mean age was 53.1 years (range,19-86 years). First, the 
clinical characteristics of thymoma with or without MG at the time of operation were 
compared. 98 of 216 cases, AchRAb data was obtained, were then classified into three 
groups according to presence of MG and AchRAb (Group A, positive titer of AchRAb 
without MG; Group B, negative titer of AchRAb without MG; Group C, positive titer of 
AchRAb with MG). Clinical characteristics after surgery using long term follow-up data 
(mean follow-up,6.1 years) were compared and analyzed among groups.  Results: MG 
was present in 62 cases (28.7%). Post-thymectomy MG occurred in 3 cases (1.4%). None of 
the 9 thymic epithelial tumors other than thymoma were associated with MG. Although 
tumor sizes were significantly smaller in the MG group than in the non-MG group (43.5 
mm vs. 57.5 mm, p=0.001), no significant differences in Masaoka staging, histology 
or recurrence rate were seen according to presence of MG. Clinical course showed no 
direct interaction between thymoma relapse and worsening of MG. In Group A (11 case), 
Group B (57 cases), and Group C (30 cases), 5-year disease-free survival rates were 75%, 
72%, and 78%, respectively. No significant differences were apparent between groups. 
Positive ratio of AchRAb titer was 100% in the presence of MG and 16.1% in the absence 
of MG. AchRAb titers showed no postoperative improvement in Group A. In contrast, 
AchRAb titer showed a >20% postoperative decrease in 64% of Group C. AchRAb in 
WHO type B1 showed no postoperative improvement in 4 of 5 cases. In contrast, AchRAb 
showed postoperative improvement in all 7 cases of type B2. A significant difference was 
apparent between these two groups (p=0.02). Seven of 10 recurrent cases demonstrated 
different histological subtypes at the time of relapse and AchRAb at recurrence exhibited 
reversed response from initial response.  Conclusion: Thymoma and MG are closely 
related. However, there seem to be no direct interactions between thymoma and MG. 
Elevated AchRAb levels show postoperative improvement in thymoma with MG, but 
not in thymoma without MG. Because AchRAb exhibited different responses in similar 
histological subtypes, thymoma might be classifiable according to biological activity. The 
histological typing of thymoma and response of AchRAb tend to differ between relapse 
and onset. Although the clinical significance of AchRAb itself remains uncertain in this 
study, these findings suggest that recurrent thymomas undergo transformation into 
tumors with diverse histology and biology. Classification according to biological activity 
may be useful in determining characteristics of thymoma. 
Keywords: myasthenia gravis, anti-acetylcholine receptor antibody, thymoma
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IT-009: PARADOXICAL SIGNAL PATTERN OF MEDIASTINAL 
CYSTS ON T2-WEIGHTED MR IMAGING:PHANTOM AND CLINI-
CAL STUDY
Ken Ueda, Masahiro Yanagawa, Takashi Ueguchi, Yukihisa Sato, Misa Kawai, Tomoko 
Gyobu, Hiromitsu Sumikawa, Osamu Honda, Noriyuki Tomiyama  
Radiology, Osaka University Graduate School Of Medicine, Suita/JAPAN
Background: Mediastinal cysts, which especially located at anterior mediastinum, 
often show low signal intensity on T2-weighted images. This paradoxical signal pattern 
may cause misinterpretation in assessment of cystic lesions. Our aim is to evaluate 
the intracystic MR signal intensity of mediastinal cystic masses on T2-weighted 
images.  Methods: Phantom study was performed to evaluate the signal intensity of 
mediastinal cystic mass phantom (rubber balloon containing water) adjacent to cardiac 
phantom pulsing at the rate of 60 times a minute. T2-weighted images (sequence, fast 
spin echo [FSE] and single shot fast spin echo [SSFSE]; slice thickness, 3mm and 5mm, 
respectively) using cardiac gating were scanned for mediastinal cystic mass phantom. 
This study also included 33 patients (16 men, 17 women; age range, 19-85 years) 
with mediastinal cystic masses, consisting of thymic cysts or pericardial cysts. In all 
patients, T2-weighted images (FSE and SSFSE) using cardiac gating were scanned. Two 
radiologists independently evaluated whether the signal intensity was uniform or not 
and evaluated the degree of the signal intensity compared with that of muscle (0;iso-
low, 1; slight high, 2;high, 3;very high). Final evaluation was decided by consensus. 
Each circular region of interest (ROI) at the center of the cystic mass and at the center 
of the muscle was manually positioned on the standard MR console: signal intensity 
of the cystic mass (cSI), that of the muscle (mSI), and the rate of cSI to mSI (cSI/mSI) 
were measured.  Results: The phantom study demonstrated that the signal intensity 
in SSFSE was more uniform than in FSE, and that the rate phantom-ROI /saline-ROI 
(0.36) in SSFSE was higher than that (0.19) in FSE. In SSFSE, the rate phantom-ROI /
saline-ROI(0.52) on thick slice section (5mm) was higher than that (0.30) on thin slice 
section (3mm). In clinical cases, the number of cases with uniform signal intensity 
in SSFSE (29/33) appeared to be more than in FSE (23/33). The degree of the signal 
intensity in SSFSE (0; n=0, 1; n=2, 2; n=15, 3; n=16) was significantly higher than in 
FSE (0; n=2, 1; n=11, 2; n=15, 3; n=5) (Wilcoxon signed rank teset, p=0.0012). The cSI/
mSI (mean±standard deviation, 123.7±46.2) in SSFSE was significantly higher than cSI/
mSI (mean±standard deviation, 98.2±37.3) in FSE (p=0.016).  Conclusion: Unexpected 
saturation and cross-talk effect can change the original signal intensity by affecting 
longitudinal magnetization when cystic masses moved along slice selective direction. 
Using SSFSE sequence makes it possible to reduce the paradoxical signal pattern on T2-
weighted images in anterior mediastinal cystic masses which are influenced on cardiac 
motion etc. Careful interpretation for the paradoxical signal pattern may be useful in 
diagnosis of mediastinal cystic mass.
Keywords: Mediastinal cyst, T2-weighted images, paradoxical signal pattern
ITMIG ORAL ABSTRACT SESSION II - November 26, 2012 10:30-12:00
IT-010: CLINICAL UTILITY OF SERUM CYFRA 21-1 IN PATIENT 
WITH THYMIC CARCINOMA
Kazunari Tateishi1, Tomonobu Koizumi2, T Agatsuma1, K Sonehara1, M Ikeda1, F 
Kinoda1, T Ichiyama1, M Hama1, K Ikegami1, Y Tokoro1, N Kobayashi1, M Horiuchi1, 
T Yokoyama1, A Ushiki1, T Kobayashi1, M Yasuo1, K Urushihata1, H Yamamoto1, M 
Hanaoka1, K Kubo1  
1First Department Of Internal Medicine,, Shinshu University School Of Medicine, 
Matsumoto/JAPAN, 2Comprehensive Cancer Center, Shinshu University School Of 
Medicine, Matsumoto/JAPAN
Background: Cytokeratin 19 and its soluble fragment (CYFRA 21-1) have been used as 
tumor marker in Non-Small-Cell Lung Cancer (NSCLC), in particular the squamaous 
cell type. CYFRA21-1 is associated with the response to therapy and a prognostic factor 
for the survival in patients with NSCLC. Although squamous cell carcinoma is the most 
common in histologic type of thymic carcinoma, the clinical utility of CYFRA21-1 
has not been evaluated in thymic carcinoma. The aim in the present study is to study 
the clinical usefulness in diagnosis, response and survival in patients with thymic 
carcinoma.  Methods: By 1990 through 2012 June, we experienced 32 patients with 
thymic carcinoma (n=32) in our hospital. Serum levels of CYFRA 21-1 were measured 
at the diagnosis. We examined the patient’s characteristics and compared with those in 
thymona (N=8). Masaoka classification was used in the present study. In addition, we 
serially measured CYFRA21-1 before and after chemotherapy (n=43), compared with the 
response to chemotherapy. The response was evaluated by RECIST. Cut off level of serum 
CYFRA 21-1 was set 3.5ng/ml.  Results: Mean serum CYFRA21-1 in thymic carcinoma 
was 19.3 ng/ml. Serum levels of CYFRA 21-1 over 3.5ng/ml at the diagnosis of thymic 
carcinoma was 46.9%, which was significantly higher than thymona (0%). Serum levels 
of CYFRA 21-1 at diagnosis showed a tendency to increase with advance in stages, but 
were not significantly associated with the stage included in age, sex, performance status, 
a smoking history. Serial measurements of CYFRA21-1 were significantly correlated 
with chemotherapy response. There was no significant difference in survival between 
increased and normal level of CYFRA21-1. However, patients with over 5.0ng/ml showed 
significantly shorter survival than that in less 5.0ng/ml.  Conclusion: Serum levels of 
CYFRA 21-1 might be reliable markers for follow up of therapy. Increased CYFRA21-1 
over 5.0 ng/ml could be predictive for worse prognosis in patients with thymic carcinoma.
Keywords: thymic carcinoma, tumor marker, CYFRA 21-1
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IT-011: ANALYSIS OF INVASIVENESS OF THYMIC EPITHELIAL 
TUMORS
Yaushi Nakagawa1, Kazuya Kondo2, Yukikiyo Kawakami1, Hiromitsu Takizawa1, 
Mitsuteru Yoshida1, Hiromitsu Takizawa1, Akira Tangoku1  
1Thoracic Endocrine Surgery And Oncology, The University Of Tokushima, Tokushima/
JAPAN, 2Department Of Oncological Medical Services, Institute Of Health Biosciences, 
The University Of Tokushima, Tokushima/JAPAN
Background: Thymoma and thymic carcinoma are tumors arising from thymic epithelial 
cells, and capable to invade surrounding organs. They are classified into 6 groups, type A, 
AB, B1, B2, B3, and carcinoma. Advanced clinical stage, type B3 thymoma and carcinoma 
are associated with poorer prognosis. It is difficult to evaluate the potential of invasiveness 
of thymic epithelial tumors according to the cytology. We reported that the expression of 
matrix-metalloproteinase (MMP)-2 and Tissue inhibitors of metalloproteinase (TIMP)-
2 were correlated with the poor prognostic variables in patients with thymic epithelial 
tumors. Methods: Tumor tissue samples were obtained from 27 patients with thymic 
epithelial tumors between 1974 and 2001 at Tokushima University Hospital. RT-PCR 
analysis was perfomed using Taqman Low density Arrays for 45 genes associated with 
MMPs. We found that 5 genes, including A Disintegrin and metalloproteinase(ADAM)-9, 
ADAM-10, ADAMTS-9, ADAMTS-12 and TIMP-1　were associated with clinical stages of 
the thymic epithelial tumors. Five-micrometer-thick, formalin-fixed, paraffin-embedded 
tissue samples were immunostained using specific antigens for ADAM-9, ADAMTS-9. 
Results: ADAM-9 was expressed in 8 of 25(32%) stage I or II thymic epithelial tumors, 
whereas in 9 of 13(69%) tumors at stage III or IV, respectively. ADAM-9 was not detected 
in type A or AB thymomas, whereas detected in 4 of 9(44%) of carcinomas. ADMTS-9 was 
detected in 9 of 25(36%) tumors at stage I or II, whereas in 7 of 13(54%) tumors at stage 
III or IV. It was detected in all types of thymic epithelial tumors. Conclusion: Five genes 
including ADAM-9 were associated with invasiveness of epithelial tumors.
Keywords: invasiveness, thymoma, thymic carcinoma
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IT-012: PROGNOSTIC VALUE OF 2-[18F]-FLUORO-2-DEOXY-D-
GLUCOSE UPTAKE ON POSITRON EMISSION TOMOGRAPHY 
AND BIOLOGIC MARKERS IN THYMIC EPITHELIAL TUMORS
Vincenzo Ambrogi1, Federico Tacconi1, Francesco Sellitri1, Orazio Schillaci2, Tommaso 
C Mineo1  
1Thoracic Surgery, Tor Vergata University, Rome/ITALY, 2Dept Of Biopathology And 
Imaging, Tor Vergata University, Rome/ITALY
Background: 2-[18F]-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission 
tomography (PET) may predict the grade of malignancy and prognosis in many tumors 
even though this possibility has to be still proved in the case of thymic epithelial tumors. 
Biologic markers related to cell proliferation may be over-expressed in this setting and 
they could be correlated to 18F-FDG uptake. We analyzed the correlation between 
the biologic markers and 18F-FDG uptake investigating the prognostic impact of each 
variable either as single or combined indicators. Methods: We reviewed the specimen of 
49 patients with thymic epithelial tumors who underwent 18F-FDG PET. Tumor sections 
were stained by immunohistochemistry for glucose transporter 1 (GLUT1), hypoxia-
inducible factor-(HIF)-1alpha, vascular endothelial growth factor (VEGF), microvessels 
density (MVD) by CD31 and CD34, cell cycle control (p53, p21,p27) and apoptosis (bcl-2) 
markers. The expressions of all these markers were scored as low and high according 
to the median value. Relationships between 18F-FDG PET standard uptake values 
and all these markers were studied by non-parametric tests. Survival studies were also 
conducted by Kaplan-Meier method and log rank test. Results: There was a positive 
correlation between 18F-FDG uptake and GLUT1 (P=0.0017), HIF-1alpha (P=0.0036), 
VEGF (P=0.0009), MVD (P=0.0021), p53 (P=0.0002) p21 (P=0.0012) and p27 (P=0.0002), 
but not with bcl-2. High standardize value (>4.5) of 18F-FDG uptake (P=0.042), high 
expression of GLUT1 (P=0.016), HIF-1alpha (P=0.034), VEGF (P=0.026), MVD by 
CD31(P=0.043) and CD34 (P=0.031), and p53 (P=0.038) as well as low expression of p21 
(P=0.011) and p27 (P=0.0023) were also significantly associated with shorter survival. 
The prognostic power of 18F-FDG was significantly enhanced when combined with low 
value expression of p21 and p27 (p<0.0001). Conclusion: Standardize values of 18F-FDG 
uptake in thymic epithelial tumors are correlated to glucose metabolism (GLUT1), 
hypoxia (HIF-1alpha), angiogenesis (VEGF, MVD by CD31 and CD34), and cell cycle 
regulator (p53,p21 and p27). Each of these variable was significantly associated to the 
prognosis. The prognostic power of high uptake value of 18F-FDG was increased when 
combined low value expression of p21 and p27.
Keywords: PET, Thymic epthelial tumor
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IT-013: THE USEFULNESS OF FDG-PET/CT AND THE RELA-
TIONSHIP BETWEEN FDG UPTAKE AND THE EXPRESSION OF 
HYPOXIA INDUCIBLE FACTOR-1α, GLUCOSE TRANSPORTER-1 
AND VASCULAR ENDOTHELIAL GROWTH FACTOR IN THYMIC 
EPITHELIAL TUMOR
Yukikiyo Kawakami1, Kazuya Kondo2, Yohei Sadohara1, Koichiro Kajiura1, H Toba1, 
Yasushi Nakagawa1, Hiromitsu Takizawa1, Mitsuteru Yoshida1, Koichiro Kenzaki1, Shoji 
Sakiyama1, Akira Tangoku1  
1Thoracic Endocrine Surgery And Oncology, Tokushima University School Of Medicine, 
Tokushima/JAPAN, 2Dept. Of Oncological Medical Srevices, Tokushima University, 
Tokushima/JAPAN
Background: In recent years, several studies have demonstrated the usefulness of 
FDG-PET in thymic epithelial tumors. And the overexpression of biomarkers such 
as HIF-1α, VEGF and Glut-1 has been reported as important factors to increase FDG 
uptake in various malignant tumors. But only a few studies demonstrated that the same 
phenomenon was also recognized in thymic epithelial tumors. The purpose of this study 
is to evaluate the usefulness of FDG-PET/CT and the relationships among the expression 
of HIF-1α, Glut-1 and VEGF, histological type, other clinical factors and FDG uptake 
in thymic epithelial tumor. Methods: Between December 2005 and February 2011, 33 
patients (15 males and 18 females, mean age: 60.2 (27-84) years) with a histologic diagnosis 
of thymic epithelial tumor were retrospectively reviewed. All type tumors were regrouped 
into 3 subgroups between low-risk thymomas (types A, AB and B1), high-risk thymomas 
(types B2 and B3) and thymic carcinoma according to WHO classification. Tumor 
contour, pattern of FDG uptake, tumor size and SUVmax were obtained. Sections were 
stained by immunohistochemistry for HIF-1α, Glut-1 and VEGF, and these expressions 
were evaluated using grading scales. Results: There were 15 low-risk thymomas (3 type 
A, 3 type AB and 9 type B1), 10 high-risk thymomas (7 type B2 and 3 type B3) and 8 
thymic carcinomas (7 carcinomas and 1 atypical carcinoid). The Masaoka’s stage was 
stage I in 10 patients, stage II in 4, stage III in 8, stage IV in 11. The mean tumor size of all 
tumors was 47.5 (18-115) mm. And the mean tumor size of low-risk thymomas, high-risk 
thymomas and thymic carcinoma were 49.2, 34.7 and 60.1 mm, respectively. The mean 
SUVmax of all tumors was 4.2 ± 2.2 (0.7-8.3). According to WHO classification, the mean 
SUVmax was 3.7 ± 2.0 in low-risk thymomas, 3.5 ± 2.1 in high-risk thymomas and 5.9 ± 
1.9 in thymic carcinoma, respectively. SUVmax for thymic carcinoma was significantly 
greater than that for thymomas (p=0.008). According to Masaoka’s classification, the 
mean SUVmax was 2.4 ± 1.3 in stage I, 3.7 ± 1.8 in stage II, 5.1 ± 1.9 in stage III and 5.3 
± 2.2 in stage IV . The mean SUVmax in stage III and IV were significantly greater than 
that in stage I (p=0.002). Regarding the mean scoring of HIF-1α, Glut-1 and VEGF, 
increasing trends were observed in the order low-risk thymomas to high-risk thymomas 
to thymic carcinoma. Tumor size revealed a significant correlation with SUVmax and the 
expression of HIF-1α showed moderate association but the expression of Glut-1 showed 
no correlation. Regarding correlations between the expression of 3 markers, there were 
moderate associations between HIF-1α and Glut-1, and HIF-1α and VEGF, and significant 
correlation between Glut-1 and VEGF. Conclusion: The pattern of FDG uptake and 
SUVmax are useful in the differential diagnosis of thymic epithelial tumor. Furthermore, 
the expression of HIF-1α, Glut-1 and VEGF might be associated with malignant nature of 
thymic epithelial tumor. However, FDG uptake might be dependent on tumor size rather 
than Glut-1 overexpression.
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IT-014: PRIMARY THYMIC CARCINOID TUMORS: CLINICOPATH-
OLOGIC STUDY IN 36 PATIENTS
Yang Zhao, Wentao Fang  
Department Of Thoracic Surgery, Shanghai Chest Hospital, Shanghai/CHINA
Background: Thymic carcinoids is a rare neoplasm with its clinical behavior still 
undefined. Methods: Thirty-six patients with thymic carcinoids were retrospectively 
reviewed. Clinical-pathological characteristics and their relationship with prognosis 
were studied. Results: There were 30 males and 6 females with a median age of 53.4 years 
(range 32 to 78 years). They were classified as typical carcinoids (16) and atypical 
carcinoids (20) histologically. The tumors were found at Masaoka-Koga stage I in 3 
(8.3%), II in 9 (25%), III in 23 (63.9%), and IV in 1 (2.8%) patients. Five-year overall 
survival was 65.1% and 5-year progression-free survival was 32.9%. Pure local recurrence 
was evident in 1 patients, regional relapse were in six patients, and 11 patients developed 
distant metastasis. Only the completeness of surgical resection was significant 
prognostic factor in multivariate Cox regression analysis (P=0.033) with the hazard 
ration=3.316 (95%: 1.100-9.992). The tumor size of 10.1cm or above was found to be a 
worse prognostic factor with the progression-free survival (P=0.014) and hazard 
ration=4.584 (95%: 1.363-15.419). 
 
Fig.1. Survival curve of thymic carcinoid: overall survival. ( 5-year overall survival was 
65.1%) 
 
 
 
Fig.2. Kaplan-Meier survival analysis with log-rank test for patients with thymic 
carcinoid to extent of surgical resection (P=0.033 and HR=3.316). 
Conclusion: Unlike thymomas, thymic carcinoids may have unique features and clinical 
behaviors. The current staging system for thymomas may not be able to predict prognosis 
of thymic carcinoids. Radical resection seems to be an important indicator for poor 
survival. Larger tumor may relapse more early. Because of its rarity, collaborative effort 
is needed in future study.
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